Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
- Equal contributors
1 Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen 361004, China
2 Institute of Hematology, Fujian Union Hospital, Fuzhou, China
3 Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
Cancer Cell International 2012, 12:38 doi:10.1186/1475-2867-12-38Published: 23 August 2012
Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B –cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (fludarabine, cyclophosphamide, rituximab) has been shown to be better than fludarabine alone and fludarabine plus cyclophosphamide for IL. In FOLL05 trial, R-CHOP was compared with R-CVP (cyclophosphamide, vincristine, prednisone) and R-FM (fludarabine, mitoxantrone). The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (bendamustine, rituximab) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.